Amylyx 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases  1 Product   1 Trial   3 News 
18 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
avexitide (exendin 9-39) / Amylyx
ACTRN12614001117606: The role of glucagon-like peptide-1 (GLP-1) in glycaemic, triglyceride and energy expenditure responses to fat in type 2 diabetes.

Recruiting
4
20
 
Dr Tanya Little, Novartis Pharmaceuticals Australia Pty. Ltd.
Type 2 diabetes
 
 
NCT04459338: A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion

Completed
3
11
US
Exendin-9,39, Saline
Adrian Vella, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Healthy
06/22
06/22
NCT04466566: A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics

Recruiting
3
40
US
Saline, Exendin-9,39
Adrian Vella, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Healthy
09/25
12/25
LUCIDITY, NCT06747468: Avexitide for Treatment of Post-Bariatric Hypoglycemia

Recruiting
3
75
US
Avexitide, exendin 9-39, Placebo
Amylyx Pharmaceuticals Inc.
Post Bariatric Hypoglycemia
03/26
10/26
NCT06967558: The Role of Islet GLP-1 in the Pathogenesis of Prediabetes

Not yet recruiting
2
60
US
Exendin 9-39, Saline
Mayo Clinic
PreDiabetes
10/27
03/28
NCT06972407: The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans

Not yet recruiting
2
80
US
Exendin 9-39, Saline
Mayo Clinic
Genetic Predisposition, Type2diabetes
12/28
03/29
NCT01803451: Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

Recruiting
1
80
US
exendin-(9-39), no other name for exendin-(9-39), exendin -(9-39)
The University of Texas Health Science Center at San Antonio
Post-bariatric Surgery
08/25
08/26
NCT00992901: Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

Recruiting
1
160
US
Exendin-(9-39), No other name for Exendin-(9-39), Atropine, Atropine sulfate, GLP-1 and GIP, No other names for GLP-1 and GIP.
The University of Texas Health Science Center at San Antonio
Post Bariatricsurgery, Hypoglycemia
08/25
08/26
NCT02823665: The Effects of Bariatric Surgeries on Glucose Metabolism

Recruiting
1
200
US
Exendin-(9-39), no other name for Exendin-(9-39), Atropine, Atropine sulfate
The University of Texas Health Science Center at San Antonio, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Post Bariatric Surgery, Gastric Bypass, Sleeve Gastrectomy, Hypoglycemia After Gastric Bypass
08/25
08/26
NCT06498063: The Underlying Mechanisms Regarding the Effect of Glucagon on the Kidneys Will be Investigated in Healthy Males.

Recruiting
N/A
10
Europe
Glucagon, Placebo, Glucagon and exendin 9-39
Ali Asmar, University of Copenhagen, The Augustinus Foundation, Denmark., The Novo Nordic Foundation
Kidney Diseases
03/25
07/25
Relyvrio (phenylbutyrate/taurursodiol) / Amylyx
2022-002348-33: A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants with Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-004 (PHOENIX) Estudio de extensión de etiqueta abierta de Fase IIIb para evaluar la seguridad y tolerabilidad de AMX0035 hasta 108 semanas en participantes adultos con esclerosis lateral amiotrófica (ELA) previamente inscritos en el estudio A35-004 (PHOENIX)

Not yet recruiting
3
600
Europe
AMX0035, AMX0035, Oral powder
Amylyx Pharmaceuticals Inc., AMYLYX PHARMACEUTICALS Inc., Amylyx Pharmaceuticals Inc.
ALS (amyotrophic lateral sclerosis) ELA (esclerosis lateral amiotrófica), ALS ELA, Diseases [C] - Nervous System Diseases [C10]
 
 
Phoenix, NCT05021536 / 2021-000250-26: Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment

Active, not recruiting
3
664
Europe, US
Placebo, AMX0035
Amylyx Pharmaceuticals Inc.
Amyotrophic Lateral Sclerosis
01/24
01/26
NCT05619783 / 2022-002348-33: Extension Study Evaluating The Safety And Tolerability of AMX0035

Completed
3
352
Europe
AMX0035, RELYVRIO
Amylyx Pharmaceuticals Inc., Amylyx Pharmaceuticals Inc.
Amyotrophic Lateral Sclerosis
10/24
10/24
NCT04516096: A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)

Completed
2/3
28
US
AMX0035
Amylyx Pharmaceuticals Inc.
Amyotrophic Lateral Sclerosis
12/22
01/23
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
HELIOS, NCT05676034: AMX0035 in Adult Patients With Wolfram Syndrome

Active, not recruiting
2
12
US
AMX0035, Proprietary formulation of taurursodiol and sodium phenylbutyrate
Amylyx Pharmaceuticals Inc.
Wolfram Syndrome
07/24
12/26
NCT04987671: Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

Active, not recruiting
1/2
14
US
AMX0035
Amylyx Pharmaceuticals Inc.
ALS
05/22
09/23
AMX0114 / Amylyx
LUMINA, NCT06665165: AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

Recruiting
1
48
Canada, US
AMX0114, Placebo
Amylyx Pharmaceuticals Inc.
ALS
02/27
10/27
Undisclosed Bax/Bak inhibitor / Amylyx, Sunnybrook Research Institute
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
avexitide (exendin 9-39) / Amylyx
ACTRN12614001117606: The role of glucagon-like peptide-1 (GLP-1) in glycaemic, triglyceride and energy expenditure responses to fat in type 2 diabetes.

Recruiting
4
20
 
Dr Tanya Little, Novartis Pharmaceuticals Australia Pty. Ltd.
Type 2 diabetes
 
 
NCT04459338: A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion

Completed
3
11
US
Exendin-9,39, Saline
Adrian Vella, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Healthy
06/22
06/22
NCT04466566: A Study to Evaluate the Effect of Genetic Variation on Beta-cell Function During Fasting and Hyperglycemia in Nondiabetics

Recruiting
3
40
US
Saline, Exendin-9,39
Adrian Vella, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Healthy
09/25
12/25
LUCIDITY, NCT06747468: Avexitide for Treatment of Post-Bariatric Hypoglycemia

Recruiting
3
75
US
Avexitide, exendin 9-39, Placebo
Amylyx Pharmaceuticals Inc.
Post Bariatric Hypoglycemia
03/26
10/26
NCT06967558: The Role of Islet GLP-1 in the Pathogenesis of Prediabetes

Not yet recruiting
2
60
US
Exendin 9-39, Saline
Mayo Clinic
PreDiabetes
10/27
03/28
NCT06972407: The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans

Not yet recruiting
2
80
US
Exendin 9-39, Saline
Mayo Clinic
Genetic Predisposition, Type2diabetes
12/28
03/29
NCT01803451: Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

Recruiting
1
80
US
exendin-(9-39), no other name for exendin-(9-39), exendin -(9-39)
The University of Texas Health Science Center at San Antonio
Post-bariatric Surgery
08/25
08/26
NCT00992901: Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

Recruiting
1
160
US
Exendin-(9-39), No other name for Exendin-(9-39), Atropine, Atropine sulfate, GLP-1 and GIP, No other names for GLP-1 and GIP.
The University of Texas Health Science Center at San Antonio
Post Bariatricsurgery, Hypoglycemia
08/25
08/26
NCT02823665: The Effects of Bariatric Surgeries on Glucose Metabolism

Recruiting
1
200
US
Exendin-(9-39), no other name for Exendin-(9-39), Atropine, Atropine sulfate
The University of Texas Health Science Center at San Antonio, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Post Bariatric Surgery, Gastric Bypass, Sleeve Gastrectomy, Hypoglycemia After Gastric Bypass
08/25
08/26
NCT06498063: The Underlying Mechanisms Regarding the Effect of Glucagon on the Kidneys Will be Investigated in Healthy Males.

Recruiting
N/A
10
Europe
Glucagon, Placebo, Glucagon and exendin 9-39
Ali Asmar, University of Copenhagen, The Augustinus Foundation, Denmark., The Novo Nordic Foundation
Kidney Diseases
03/25
07/25
Relyvrio (phenylbutyrate/taurursodiol) / Amylyx
2022-002348-33: A Phase IIIb, Open Label Extension Study Evaluating The Safety And Tolerability of AMX0035 Up To 108 Weeks In Adult Participants with Amyotrophic Lateral Sclerosis (ALS) Previously Enrolled In Study A35-004 (PHOENIX) Estudio de extensión de etiqueta abierta de Fase IIIb para evaluar la seguridad y tolerabilidad de AMX0035 hasta 108 semanas en participantes adultos con esclerosis lateral amiotrófica (ELA) previamente inscritos en el estudio A35-004 (PHOENIX)

Not yet recruiting
3
600
Europe
AMX0035, AMX0035, Oral powder
Amylyx Pharmaceuticals Inc., AMYLYX PHARMACEUTICALS Inc., Amylyx Pharmaceuticals Inc.
ALS (amyotrophic lateral sclerosis) ELA (esclerosis lateral amiotrófica), ALS ELA, Diseases [C] - Nervous System Diseases [C10]
 
 
Phoenix, NCT05021536 / 2021-000250-26: Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment

Active, not recruiting
3
664
Europe, US
Placebo, AMX0035
Amylyx Pharmaceuticals Inc.
Amyotrophic Lateral Sclerosis
01/24
01/26
NCT05619783 / 2022-002348-33: Extension Study Evaluating The Safety And Tolerability of AMX0035

Completed
3
352
Europe
AMX0035, RELYVRIO
Amylyx Pharmaceuticals Inc., Amylyx Pharmaceuticals Inc.
Amyotrophic Lateral Sclerosis
10/24
10/24
NCT04516096: A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)

Completed
2/3
28
US
AMX0035
Amylyx Pharmaceuticals Inc.
Amyotrophic Lateral Sclerosis
12/22
01/23
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
HELIOS, NCT05676034: AMX0035 in Adult Patients With Wolfram Syndrome

Active, not recruiting
2
12
US
AMX0035, Proprietary formulation of taurursodiol and sodium phenylbutyrate
Amylyx Pharmaceuticals Inc.
Wolfram Syndrome
07/24
12/26
NCT04987671: Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

Active, not recruiting
1/2
14
US
AMX0035
Amylyx Pharmaceuticals Inc.
ALS
05/22
09/23
AMX0114 / Amylyx
LUMINA, NCT06665165: AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

Recruiting
1
48
Canada, US
AMX0114, Placebo
Amylyx Pharmaceuticals Inc.
ALS
02/27
10/27
Undisclosed Bax/Bak inhibitor / Amylyx, Sunnybrook Research Institute
No trials found

Download Options